Business Description
Bellerophon Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US0787711029
Description
Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 547.75 | |||||
| Equity-to-Asset | 0.75 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -76.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 15 | |||||
| 3-Year EPS without NRI Growth Rate | 15.6 | |||||
| 3-Year FCF Growth Rate | 13.5 | |||||
| 3-Year Book Growth Rate | -30.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.49 | |||||
| 9-Day RSI | 47.81 | |||||
| 14-Day RSI | 48.65 | |||||
| 12-1 Month Momentum % | -99.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.96 | |||||
| Quick Ratio | 3.96 | |||||
| Cash Ratio | 3.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.2 | |||||
| Shareholder Yield % | -130.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -195.66 | |||||
| Net Margin % | -164.06 | |||||
| FCF Margin % | -218.78 | |||||
| ROE % | -154.68 | |||||
| ROA % | -87.73 | |||||
| ROIC % | -1271.29 | |||||
| ROC (Joel Greenblatt) % | -3962.3 | |||||
| ROCE % | -184.46 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.09 | |||||
| PB Ratio | 0.18 | |||||
| Price-to-Tangible-Book | 0.18 | |||||
| EV-to-EBIT | 1.31 | |||||
| EV-to-EBITDA | 1.31 | |||||
| EV-to-Revenue | -2.56 | |||||
| EV-to-Forward-Revenue | 6.36 | |||||
| EV-to-FCF | 1.18 | |||||
| Price-to-Net-Current-Asset-Value | 0.18 | |||||
| Price-to-Net-Cash | 0.21 | |||||
| Earnings Yield (Greenblatt) % | 76.34 | |||||
| FCF Yield % | -1863.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BLPH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bellerophon Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.64 | ||
| EPS (TTM) ($) | -0.84 | ||
| Beta | 2.35 | ||
| Volatility % | 137.91 | ||
| 14-Day RSI | 48.65 | ||
| 14-Day ATR ($) | 0.005338 | ||
| 20-Day SMA ($) | 0.055392 | ||
| 12-1 Month Momentum % | -99.36 | ||
| 52-Week Range ($) | 0.029 - 11.15 | ||
| Shares Outstanding (Mil) | 12.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bellerophon Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bellerophon Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bellerophon Therapeutics Inc Frequently Asked Questions
What is Bellerophon Therapeutics Inc(BLPH)'s stock price today?
The current price of BLPH is $0.05. The 52 week high of BLPH is $11.15 and 52 week low is $0.03.
When is next earnings date of Bellerophon Therapeutics Inc(BLPH)?
The next earnings date of Bellerophon Therapeutics Inc(BLPH) is 2024-05-15 Est..
Does Bellerophon Therapeutics Inc(BLPH) pay dividends? If so, how much?
Bellerophon Therapeutics Inc(BLPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers